347 related articles for article (PubMed ID: 35527057)
1. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
[TBL] [Abstract][Full Text] [Related]
2. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
Jeong HS; Chun BC
PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
[TBL] [Abstract][Full Text] [Related]
4. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
[TBL] [Abstract][Full Text] [Related]
6. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
[TBL] [Abstract][Full Text] [Related]
8. Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
Xu S; Hong V; Sy LS; Glenn SC; Ryan DS; Morrissette KL; Nelson JC; Hambidge SJ; Crane B; Zerbo O; DeSilva MB; Glanz JM; Donahue JG; Liles E; Duffy J; Qian L
Vaccine; 2022 May; 40(23):3150-3158. PubMed ID: 35465977
[TBL] [Abstract][Full Text] [Related]
9. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
11. Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
Choe YJ; Ahn YH; Gwak E; Jo E; Kim J; Choe SA
Pediatr Nephrol; 2024 Feb; 39(2):625-629. PubMed ID: 37880380
[TBL] [Abstract][Full Text] [Related]
12. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
[TBL] [Abstract][Full Text] [Related]
14. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
[TBL] [Abstract][Full Text] [Related]
15. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
16. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study.
Li X; Ostropolets A; Makadia R; Shaoibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard M; Ryan P; Hripcsak G; Prieto-Alhambra D
medRxiv; 2021 Apr; ():. PubMed ID: 33791732
[TBL] [Abstract][Full Text] [Related]
19. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study.
Voss EA; Shoaibi A; Yin Hui Lai L; Blacketer C; Alshammari T; Makadia R; Haynes K; Sena AG; Rao G; van Sandijk S; Fraboulet C; Boyer L; Le Carrour T; Horban S; Morales DR; Martínez Roldán J; Ramírez-Anguita JM; Mayer MA; de Wilde M; John LH; Duarte-Salles T; Roel E; Pistillo A; Kolde R; Maljković F; Denaxas S; Papez V; Kahn MG; Natarajan K; Reich C; Secora A; Minty EP; Shah NH; Posada JD; Garcia Morales MT; Bosca D; Cadenas Juanino H; Diaz Holgado A; Pedrera Jiménez M; Serrano Balazote P; García Barrio N; Şen S; Üresin AY; Erdogan B; Belmans L; Byttebier G; Malbrain MLNG; Dedman DJ; Cuccu Z; Vashisht R; Butte AJ; Patel A; Dahm L; Han C; Bu F; Arshad F; Ostropolets A; Nyberg F; Hripcsak G; Suchard MA; Prieto-Alhambra D; Rijnbeek PR; Schuemie MJ; Ryan PB
EClinicalMedicine; 2023 Apr; 58():101932. PubMed ID: 37034358
[TBL] [Abstract][Full Text] [Related]
20. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database.
Lee S; Jo H; Lee H; Lee H; Lee J; Kim HJ; Kang J; Jacob L; Smith L; Rahmati M; López Sánchez GF; Dragioti E; Jeon H; Cho JM; Choi Y; Park J; Woo S; Yon DK
J Med Virol; 2024 Jun; 96(6):e29693. PubMed ID: 38859751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
